QNCXPhases
Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board
Quince Therapeutics has established a Scientific Advisory Board (SAB) comprising experts in pulmonary medicine to advance the development of LAM-001, an inhaled formulation of rapamycin. The SAB will focus on multiple pulmonary indications, including pulmonary hypertension associated with interstitial lung disease. The company is optimistic about LAM-001's potential benefits based on positive Phase 2a trial results.
Read more →QNCXPhases
▼ -13.5%on this news
UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD
Quince Therapeutics announced positive results from its Phase 2a study of LAM-001, an inhaled mTOR inhibitor, in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The study demonstrated significant improvements in lung function, including a 67.4-meter increase in six-minute walk distance (6MWD) and a 33.9% reduction in pulmonary vascular resistance (PVR). A Phase 2b trial is set to begin in mid-2026, with topline data expected in early 2028.
Read more →QNCXGeneral
▼ -13.5%on this news
Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline
Quince Therapeutics has acquired Orphai Therapeutics, gaining access to LAM-001, an inhaled rapamycin formulation targeting rare pulmonary diseases. The acquisition is supported by a $187 million private placement, with $115 million upfront. Quince plans to initiate Phase 2b trials for pulmonary hypertension associated with interstitial lung disease and bronchiolitis obliterans syndrome, with data expected in 2027 and 2028.
Read more →QNCXPhases
▼ -13.5%on this news
Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD Data from Phase 2a study of LAM-001 on top of standard of care in
Quince Therapeutics, Inc. announced promising results from its Phase 2a study of LAM-001, an inhaled formulation aimed at treating patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The study showed significant improvements across various clinical endpoints, including a notable increase in the six-minute walk distance (6MWD) and reductions in pulmonary vascular resistance (PVR). The data supports LAM-001's potential as an effective therapy in this area of unmet medical need. The company plans to advance LAM-001 into a Phase 2b trial later this year.
Read more →QNCXGeneral
▲ +15.6%on this news
Quince Therapeutics Settles Approximately $16.4 Million of Debt
Quince Therapeutics has settled approximately $16.4 million of debt. This financial move may impact the company's balance sheet positively, but further details on the implications for operations or future plans are not provided.
Read more →QNCXPhases
▼ -37.1%on this news
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
Quince Therapeutics announced that its pivotal Phase 3 NEAT trial for eDSP in Ataxia-Telangiectasia did not meet its primary or key secondary endpoints, leading the company to halt further development of the drug. Despite the lack of efficacy, eDSP was well tolerated with no major safety issues reported. The company aims to preserve cash and explore other options.
Read more →QNCXPhases
Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting
Quince Therapeutics presented safety data from a long-term study of encapsulated dexamethasone sodium phosphate (eDSP) for children with Ataxia-Telangiectasia (A-T) at the British Paediatric Neurology Association Annual Meeting. The analysis focused on the safety profile of eDSP, which has been administered for at least two years. The company is advancing a Phase 3 clinical trial for eDSP and expects to report topline results in early 2026.
Read more →QNCXPhases
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia Primary and key secondary endpoint did not achieve statistical significance eDSP was ge
Quince Therapeutics announced the topline results from its pivotal Phase 3 NEAT clinical trial of eDSP for Ataxia-Telangiectasia. The trial did not achieve statistical significance for its primary and key secondary endpoints, leading the company to cease development of the drug. Although eDSP was well tolerated, the failure to meet expected outcomes raises concerns about its viability as a treatment option.
Read more →QNCXPhases
Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results Pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T remains on track with topline result
Quince Therapeutics recently provided an update detailing its financial results for Q3 2025 and the status of its pivotal Phase 3 NEAT clinical trial for eDSP, aimed at treating Ataxia-Telangiectasia. The trial remains on track, with topline results anticipated in the first quarter of 2026. Positive insights include a favorable safety analysis from an independent monitoring board and full participation in the open label extension study. However, the company reported a net loss, indicating ongoing financial pressures as they prepare for future regulatory submissions.
Read more →QNCXPhases
Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results Marks major milestone with completion of enrollment in pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for t
Quince Therapeutics announced a significant milestone with the completion of enrollment in its Phase 3 NEAT clinical trial for eDSP, aimed at treating Ataxia-Telangiectasia (A-T). The company also reported a cash position of approximately $35 million following a recent financing round, expected to support operations through key upcoming trial results. Additionally, Quince formed a partnership with Option Care Health to facilitate the U.S. launch of eDSP. Despite these advancements, the company reported a net loss of $16.1 million for the second quarter of 2025.
Read more →QNCXPhases
Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
Quince Therapeutics has successfully completed enrollment in the pivotal Phase 3 NEAT clinical trial for its lead product, eDSP, aimed at treating Ataxia-Telangiectasia (A-T). This milestone is significant for the company as it moves closer to potentially delivering a first treatment for this rare disease. The CEO expressed confidence in the trial's design and oversight, with topline results expected in early 2026, followed by an NDA submission later that year. A-T is a severe neurodegenerative disorder with no currently approved therapies.
Read more →QNCXPhases
Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results Plan to potentially conclude enrollment early for Phase 3 NEAT clinical trial in Ataxia-Telangiectasia (A-T) to align topline
Quince Therapeutics provided a business update and reported its first quarter 2025 financial results, revealing plans for the Phase 3 NEAT clinical trial for Ataxia-Telangiectasia. The company may conclude enrollment early by June 2025 to better align topline results with its existing cash runway. While enrollment has been slower than expected due to various challenges, the company remains hopeful for positive trial results and subsequent regulatory submissions in 2026. Quince reported a net loss of $15 million for this quarter, prompting a focus on strategic funding solutions to maintain operations.
Read more →QNCXPhases
Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results Phase 3 NEAT clinical trial exceeds 50% enrollment with new study site activations expected to accelerate screenings and randomi
Quince Therapeutics announced a significant update regarding its Phase 3 NEAT clinical trial, reporting over 50% enrollment and expecting new site activations to further boost participant screenings. The company's fiscal year 2024 financial results showed a cash position of $40.8 million, projected to sustain operations into 2026. Despite reporting a net loss for the year, Quince is progressing with plans for additional studies and has established a dedicated Scientific Advisory Board. The anticipated topline results from the NEAT trial are expected in the fourth quarter of 2025.
Read more →QNCXPhases
Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results Phase 3 NEAT clinical trial on track with 32 patients enrolled to date with majority of U.S. and European study sites now enro
Quince Therapeutics has reported a positive update regarding its Phase 3 NEAT clinical trial, noting that 32 patients have been enrolled to date. The company expects to maintain enrollment momentum and aims to complete it by Q2 2025, with topline results anticipated in Q4 2025. Additionally, Quince provided its third quarter financial results, revealing a net loss of $5.5 million, but it maintains a strong cash position sufficient to fund operations into 2026.
Read more →QNCXPhases
▼ -16.5%on this news
Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results Strong cash position expected to provide sufficient operating runway into 2026 Phase 3 topline results expected in the fourth
Quince Therapeutics has reported its financial results for Q2 2024, highlighting a strong cash position that is expected to support operations through 2026. The company is advancing its pivotal Phase 3 clinical trial for EryDex in Ataxia-Telangiectasia, with the first patient enrolled and a total of seven participants recruited. Additionally, Quince anticipates topline results in Q4 2025, paving the way for potential NDA and MAA submissions in 2026. Despite a significant net loss reported for the quarter, the company's ongoing developments and strategic initiatives showcase a promising outlook.
Read more →QNCXGeneral
Quince Therapeutics to Acquire EryDel
Quince Therapeutics plans to acquire EryDel, aiming to enhance its capabilities in developing EryDex, a treatment for Ataxia-Telangiectasia. The acquisition has been unanimously approved by both companies' boards and involves a stock-for-stock exchange, as well as potential milestone cash payments. EryDex has shown promise in prior trials with a favorable safety profile and plans for a Phase 3 trial starting in mid-2024, contingent on successful outcomes. This acquisition may position Quince for future growth, given the significant market potential of EryDex in addressing an unmet medical need.
Read more →QNCXGeneral
Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan
Quince Therapeutics has implemented a limited duration stockholder rights plan to safeguard against unsolicited acquisition proposals and control threats. The plan will be effective for one year, expiring on April 5, 2024, and includes special provisions that activate if an entity acquires a certain percentage of shares without Board approval. This strategy aims to ensure that stockholders realize long-term value while allowing the Board to evaluate strategic alternatives. Additionally, Quince is seeking a financial advisor to assist in these evaluations.
Read more →QNCXGeneral
Quince Therapeutics Details Strategic Growth Plan with Launch of New Corporate Name Strategic focus centered on advancing innovative precision therapeutics for debilitating and rare diseases Highly different
Quince Therapeutics Details Strategic Growth Plan with
Launch of New Corporate Name
Strategic focus centered on advancing innovative precision therapeutics for debilitating and rare diseases
Highly differentiated bone-targeting drug platform and lead precision bone growth mole
Read more →QNCXGeneral
Cortexyme Announces Agreement to Acquire Novosteo Expanding pipeline with addition of targeted therapeutics to treat rare skeletal diseases, bone cancer and injury Strengthening leadership team with appointment of Novost
Cortexyme Announces Agreement to Acquire Novosteo
Expanding pipeline with addition of targeted therapeutics to treat rare skeletal diseases, bone cancer and injury
Strengthening leadership team with appointment of Novosteo executives Dr. Dirk Thye as CEO and
Dr. Karen Smith as
Read more →QNCXPhases
Cortexyme Provides Regulatory Update on Development Program for Atuzaginstat in Alzheimer s Disease Double-blind phase of GAIN Trial to continue as planned, with top-line data expected Q4 2021 Open-Label Extension of atu
Cortexyme Provides Regulatory Update on Development Program for Atuzaginstat in Alzheimer s Disease
Double-blind phase of GAIN Trial to continue as planned, with top-line data expected
Open-Label Extension of atuzaginstat to stop dosing and enrollment
SOUTH SAN FRANCISCO, Cali
Read more →QNCXGeneral
Investor Contact: Chris Lowe Cortexyme, Inc. Chief Financial Officer clowe@cortexyme.com Media Contact: Hal Mackins For Cortexyme, Inc. hal@torchcomllc.com (415) 994-0040 Cortexyme Announces Pipeline Update and Anticipat
Cortexyme Announces Pipeline Update and Anticipated 2021 Milestones
Based upon successful completion of the GAIN Trial s interim analysis, pipeline expansion announced for 2021
Atuzaginstat to be studied in the PEAK trial, a new Phase 2 study for Parkinson s disease
COR588, a
Read more →QNCXGeneral
Investor Contact: Chris Lowe Cortexyme, Inc. Chief Financial Officer clowe@cortexyme.com Media Contact: Hal Mackins For Cortexyme, Inc. hal@torchcomllc.com (415) 994-0040 Cortexyme Announces First Quarter 2020 Financial
Investor Contact: Chris Lowe Cortexyme, Inc. Chief Financial Officer clowe@cortexyme.com Media Contact: Hal Mackins For Cortexyme, Inc. hal@torchcomllc.com (415) 994-0040
Cortexyme Announces First Quarter 2020 Financial Results and Provides Business Update
Inter
Read more →QNCXGeneral
Investor Contact: Chris Lowe Cortexyme, Inc. Chief Financial Officer clowe@cortexyme.com Media Contact: Hal Mackins For Cortexyme, Inc. hal@torchcomllc.com (415) 994-0040 Cortexyme Announces Fourth Quarter and Full Year
Investor Contact: Chris Lowe Cortexyme, Inc. Chief Financial Officer clowe@cortexyme.com Media Contact: Hal Mackins For Cortexyme, Inc. hal@torchcomllc.com (415) 994-0040
Cortexyme Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Busine
Read more →QNCXGeneral
Hal Mackins For Cortexyme, Inc. hal@torchcomllc.com (415) 994-0040 Cortexyme Announces $125 Million Private Placement
Media Contact: Hal Mackins For Cortexyme, Inc. hal@torchcomllc.com (415) 994-0040
Cortexyme Announces $125 Million Private Placement
SOUTH SAN FRANCISCO, Calif. February 5, 2020 Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical
company pioneeri
Read more →QNCXGeneral
Chris Lowe Chief Financial Officer Cortexyme, Inc. clowe@cortexyme.com Hal Mackins For Cortexyme, Inc. hal@torchcomllc.com (415) 994-0040 CORTEXYME, INC. ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING South San F
Contacts: Chris Lowe Chief Financial Officer Cortexyme, Inc. clowe@cortexyme.com Hal Mackins For Cortexyme, Inc. hal@torchcomllc.com (415) 994-0040
CORTEXYME, INC. ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING
South San Francisco, Calif. May 8,
Read more →